Are you interested in participating in this clinical study?
Active-controlled study to assess the efficacy, safety, and tolerability of investigational drug Baxdrostat in combination with Dapagliflozin compared with Dapagliflozin alone on chronic kidney disease (CKD) progression in participants with CKD and high blood pressure.
Inclusion criteria
-
-
- Male or females non-childbearing potential must be > 18 years of age
- EGFR ≥ 30 and < 90 ml/min/1.73 m2
- Participants with history of HTN and a SBP ≥ 130 mmhg and ≥ 120mmhg
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
-
For more information:
Call us 786-772-0510
